Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 12.67
(-0.63%)
CNY 12.67
(-0.63%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1 Million CNY | -99.05% |
| 2022 | 105.56 Million CNY | 290.25% |
| 2021 | 27.05 Million CNY | -54.84% |
| 2020 | 59.9 Million CNY | 49.6% |
| 2019 | 40.03 Million CNY | 48.3% |
| 2018 | 27 Million CNY | -44.9% |
| 2017 | 49 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 79.54 Million CNY | 7854.68% |
| 2024 Q3 | 25.42 Million CNY | -8.23% |
| 2024 Q1 | 1 Million CNY | -0.11% |
| 2023 Q4 | 1 Million CNY | 0.11% |
| 2023 FY | 1 Million CNY | -99.05% |
| 2023 Q3 | 1 Million CNY | -51.69% |
| 2023 Q2 | 2.07 Million CNY | 0.0% |
| 2023 Q1 | 2.07 Million CNY | -98.04% |
| 2022 Q3 | 56.03 Million CNY | 115.22% |
| 2022 Q2 | 26.03 Million CNY | 62.36% |
| 2022 Q1 | 16.03 Million CNY | -40.72% |
| 2022 FY | 105.56 Million CNY | 290.25% |
| 2022 Q4 | 105.56 Million CNY | 88.39% |
| 2021 Q4 | 27.05 Million CNY | -84.95% |
| 2021 Q3 | 179.7 Million CNY | 240.57% |
| 2021 Q2 | 52.76 Million CNY | 426.96% |
| 2021 FY | 27.05 Million CNY | -54.84% |
| 2021 Q1 | 10.01 Million CNY | 0.0% |
| 2020 FY | 59.9 Million CNY | 49.6% |
| 2020 Q1 | - CNY | 0.0% |
| 2020 Q4 | - CNY | 0.0% |
| 2020 Q2 | 10.01 Million CNY | 0.0% |
| 2019 FY | 40.03 Million CNY | 48.3% |
| 2018 FY | 27 Million CNY | -44.9% |
| 2017 FY | 49 Million CNY | 0.0% |